2011
October 11, 2017
|By Natasa Lagou
- Imarem®, a new generic product used in the treatment of chronic myeloid leukemia containing Imatinib as the active ingredient, successfully passed clinical testing and registration begun in the EU and other countries.
- Kapetral®, Remedica’s new generic chemotherapy product containing Capecitabine as the active ingredient and used in the treatment of metastatic breast and colorectal cancers, successfully passed clinical testing.
- A successful inspection by Pharma Aid allowed Remedica to begin supply to this non-profit organisation.